Kala Pharmaceuticals, Inc. (KALA) financial statements (2020 and earlier)

Company profile

Business Address 100 BEAVER STREET
WALTHAM, MA 02453
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments85171115
Cash and cash equivalents85171115
Receivables13  
Inventory, net of allowances, customer advances and progress billings54 
Inventory54 
Prepaid expense210
Other current assets 00
Other undisclosed current assets11 
Total current assets:105177115
Noncurrent Assets
Inventory, Noncurrent4  
Operating lease, right-of-use asset30
Property, plant and equipment321
Restricted cash and investments13120
Other undisclosed noncurrent assets 30 
Total noncurrent assets:49441
TOTAL ASSETS:154221116
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23178
Accounts payable351
Accrued liabilities21117
Debt1 7
Other undisclosed current liabilities 0 
Total current liabilities:251714
Noncurrent Liabilities
Long-term debt and lease obligation1009912
Long-term debt, excluding current maturities717012
Finance lease, liability29
Capital lease obligations29 
Liabilities, other than long-term debt  0
Other liabilities  0
Total noncurrent liabilities:1009912
Total liabilities:12511626
Stockholders' equity
Stockholders' equity attributable to parent3010590
Common stock000
Additional paid in capital325306224
Accumulated deficit(295)(201)(134)
Total stockholders' equity:3010590
TOTAL LIABILITIES AND EQUITY:154221116

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Gross profit:6  
Operating expenses(94)(65)(40)
Operating loss:(88)(65)(40)
Nonoperating income
(Investment Income, Nonoperating)
221
Interest and debt expense(8)(4)(1)
Loss before gain (loss) on sale of properties:(94)(67)(40)
Other undisclosed net loss  (2)
Net loss available to common stockholders, diluted:(94)(67)(42)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(94)(67)(42)
Comprehensive loss, net of tax, attributable to parent:(94)(67)(42)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: